News
22 December 2011
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced that effective December 21, 2011, the company completed its previously announced acquisition of iNova
30 November 2011
Rinar®, a capsaicin nasal spray for the treatment of Non-allergic Rhinitis (NAR) was recently
launched in Australia by iNova Pharmaceuticals. Non-allergic Rhinitis, a relatively unknown
condition, is irritation of the nose not caused by allergies or illness. Rinar® offers Non-allergic
Rhinitis ...
25 November 2011
(Tokyo, November 25, 2011) - Mochida Pharmaceutical Co., Ltd (Head Office: Shinjuku-ku, Tokyo,
Japan; President: Naoyuki Mochida) announces that Beselna Cream 5% (imiquimod) received
approval in Japan for the additional indication of actinic keratosis as of November 25.
22 November 2011
Mississauga, Ontario, Canada — November 20, 2011 — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that it has signed an agreement to acquire iNova, a private pharmaceutical group which sells and distributes a range of prescription and over-the-counter (OTC) ...
22 November 2011
Archer Capital (“Archer”) and Ironbridge are pleased to announce the sale, by funds advised by Archer and Ironbridge, of iNova Pharmaceuticals to Valeant Pharmaceuticals International Inc. (“Valeant”), a multinational specialty pharmaceutical company.
04 November 2011
achievit® is a new and exciting range of very low energy diet (VLED) shakes and soups formulated to assist people to reach and maintain a healthy weight.
20 October 2011
It’s not every day that company headquarters people visit a pharmacy to understand firsthand patient and consumer needs. Yet that’s what happened when marketing and medical colleagues from iNova Pharmaceuticals toured John Bell Pharmacy in Sydney.
10 March 2011
Professional education for 2011 received a timely boost this week as 21 pharmacists undertook a tour of iNova Pharmaceuticals manufacturing and laboratory facilities in Sydney. This comes hot on the heels of a similar visit only days before by new Pharmaceutical Society of Australia (PSA) ...
02 March 2011
iNova Pharmaceuticals has generously donated to the University of New South Wales (UNSW) in support of its postgraduate Pharmaceutical Medicine and Drug Development Programs. The financial support, made to the Student Travel Fund, will assist students from around the country to cover costs ...
14 December 2010
Around 35 pharmacists and pharmacy students visited the iNova Technology Centre at iNova Pharmaceuticals’ corporate headquarters in Sydney last week for a rare look into the development and manufacture of medicines destined for Australian and overseas pharmacy shelves. The manufacturing and ...
13 October 2010
iNova Pharmaceuticals (“iNova”), a growing company in the Asia-Pacific and South Africa region that markets prescription and over the counter medicines, has acquired exclusive Australian rights to a new therapy option, which will complement existing treatments for chronic obstructive ...
10 September 2010
iNova Pharmaceuticals today announced the appointment of Mr Will Delaat as a non-executive Director effective 17 August 2010.
21 May 2010
Managing both chest congestion and a sore throat has never been easier, as new DURO-TUSS™ Chesty Cough eucalyptus and menthol lozenge joins a broad and ever increasing range of DURO-TUSS™ cough medicine products, just in time for the 2010 Australian winter season. The new cool flavoured ...
19 May 2010
iNova Pharmaceuticals today announced its partner Eisai Co., Ltd. (“Eisai”) has received approval to market anti-arrhythmic Tambocor® (flecainide acetate) 50mg and 100mg tablets in Japan for the new indication of tachyarrhythmia (paroxysmal atrial fibrillation/flutter, paroxysmal ...
18 March 2010
In a world first, MetroGel™ V, South Africa’s leading vaginal gel preparation, is now available over the counter (OTC) in pharmacy as a first line therapy to treat bacterial vaginosis (BV). Women now have the convenience of going to their pharmacy for advice and assistance in treating ...
18 March 2010
iNova Pharmaceuticals is launching two new Duro-Tuss products in New Zealand, further expanding its broad range of cough therapies. Duro-Tuss Chesty Cough Liquid Forte in 100mL and 200mL, combining Bromhexine hydrochloride and expectorant Guaiphenesin, clears heavy chesty coughs and is ...
17 November 2009
Perfect spring weather, cheering onlookers and cool shirts were the order of the day as 26 Team Azep iNova cyclists, in true community spirit, finished the 2009 Multiple Sclerosis (MS) 90km Gong Ride.
06 November 2009
iNova Pharmaceuticals, one of the top five fastest growing pharmaceutical companies in Australia, today unveiled increased production capacity at its world class manufacturing, laboratory and product development facility, the iNova Technology Centre, in Sydney.
20 October 2009
Community spirit was in full swing at iNova Pharmaceuticals (“iNova”), Sydney, which today hosted a Morning Tea to raise funds for Multiple Sclerosis (MS) research. “Team Azep iNova” riders were introduced, having already exceeded the initial $10,000 fundraising goal leading up to the 2009 MS ...
15 October 2009
Pharmaceutical Society of Australia (PSA) members experienced a rare opportunity this week when a group of pharmacists toured iNova Pharmaceuticals’ manufacturing, laboratory and product development facility, the iNova Technology Centre, at the company’s corporate headquarters in Sydney.
1
2